VincentE.HerrinMDFACP

Clotting Disorder, Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Chief, Hematologic Malignancies Professor of Medicine

Dr. Herrin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1860 Chadwick Dr
Ste 351
Jackson, MS 39204
Phone+1 601-376-1288

Fax+1 601-984-5689

University of Mississippi School of MedicineFellowship, Hematology and Medical Oncology, 2000
University of Mississippi Medical CenterResidency, Internal Medicine, 1997
University of Mississippi School of MedicineClass of 1994
Mississippi CollegeBA; BS, History; Biology, 1986 - 1990

PubMed

89 citations
Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers.
Antoun Toubaji, Moujahed Achtar, Maurizio Provenzano, V. E. Herrin, Robert Behrens
Cancer Immunology, Immunotherapy. 2008-02-23
24 citations
Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer
Osama E. Rahma, V. E. Herrin, Rami A Ibrahim, Anton Toubaji, Sarah Bernstein
Journal of Translational Medicine. 2014-12-16
26 citations
A pilot clinical trial testing mutant von Hippel- Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma
Osama E. Rahma, Ed Ashtar, Ramy Ibrahim, Antoun Toubaji, B. Gause
Journal of Translational Medicine. 2010-01-28

FDA Cracks down on Stem Cell Clinics Offering Unproven TherapiesOctober 12th, 2016
MCH Blood Test: What Do MCH Levels in Blood Mean? (Evidence Based)December 6th, 2017
UMMC First in State to Offer CAR T Therapy for Persistent CancerMay 23rd, 2024